178 related articles for article (PubMed ID: 11774106)
21. Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
Blaney M; Shen V; Kerner JA; Jacobs BR; Gray S; Armfield J; Semba CP;
J Vasc Interv Radiol; 2006 Nov; 17(11 Pt 1):1745-51. PubMed ID: 17142704
[TBL] [Abstract][Full Text] [Related]
22. Restoration of patency in failing tunneled hemodialysis catheters: a comparison of catheter exchange, exchange and balloon disruption of the fibrin sheath, and femoral stripping.
Janne d'Othée B; Tham JC; Sheiman RG
J Vasc Interv Radiol; 2006 Jun; 17(6):1011-5. PubMed ID: 16778235
[TBL] [Abstract][Full Text] [Related]
23. Alteplase versus urokinase for occluded hemodialysis catheters.
Zacharias JM; Weatherston CP; Spewak CR; Vercaigne LM
Ann Pharmacother; 2003 Jan; 37(1):27-33. PubMed ID: 12503929
[TBL] [Abstract][Full Text] [Related]
24. Tunneled internal jugular catheters in adult patients: comparison of outcomes in hemodialysis versus infusion catheters.
Peynircioglu B; Ozkan F; Canyigit M; Cil BE; Balkanci F
Acta Radiol; 2007 Jul; 48(6):613-9. PubMed ID: 17611867
[TBL] [Abstract][Full Text] [Related]
25. Managing catheter dysfunction for better patient outcomes: a team approach.
Dinwiddie LC
Nephrol Nurs J; 2004; 31(6):653-60, 671; quiz 661-2. PubMed ID: 15686329
[TBL] [Abstract][Full Text] [Related]
26. Restoration of flow following haemodialysis catheter thrombus. Analysis of rt-PA infusion in tunnelled dialysis catheters.
Davies J; Casey J; Li C; Crowe AV; McClelland P
J Clin Pharm Ther; 2004 Dec; 29(6):517-20. PubMed ID: 15584939
[TBL] [Abstract][Full Text] [Related]
27. Establishing an alteplase dosing protocol for hemodialysis-catheter thrombosis.
Nguyen TV; Dikun M
Am J Health Syst Pharm; 2004 Sep; 61(18):1922-4. PubMed ID: 15487882
[No Abstract] [Full Text] [Related]
28. Successful treatment of a catheter-related right atrial thrombosis with recombinant tissue plasminogen activator and heparin.
Cesaro S; Paris M; Corrò R; Svaluto G; Zanon GF; Gamba P; Milanesi O; Messina C; Zanesco L
Support Care Cancer; 2002 Apr; 10(3):253-5. PubMed ID: 11904791
[TBL] [Abstract][Full Text] [Related]
29. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
Ponec D; Irwin D; Haire WD; Hill PA; Li X; McCluskey ER;
J Vasc Interv Radiol; 2001 Aug; 12(8):951-5. PubMed ID: 11487675
[TBL] [Abstract][Full Text] [Related]
30. Alteplase use for malfunctioning central venous catheters correlates with catheter-associated bloodstream infections.
Rowan CM; Miller KE; Beardsley AL; Ahmed SS; Rojas LA; Hedlund TL; Speicher RH; Nitu ME
Pediatr Crit Care Med; 2013 Mar; 14(3):306-9. PubMed ID: 23392362
[TBL] [Abstract][Full Text] [Related]
31. Comparison of cuffed tunneled hemodialysis catheter survival.
Rocklin MA; Dwight CA; Callen LJ; Bispham BZ; Spiegel DM
Am J Kidney Dis; 2001 Mar; 37(3):557-63. PubMed ID: 11228180
[TBL] [Abstract][Full Text] [Related]
32. Efficacy, safety, and cost of thrombolytic agents for the management of dysfunctional hemodialysis catheters: a systematic review.
Hilleman D; Campbell J
Pharmacotherapy; 2011 Oct; 31(10):1031-40. PubMed ID: 21950645
[TBL] [Abstract][Full Text] [Related]
33. Effect of mechanical brushing on survival and hemodynamic characteristics of tunneled hemodialysis catheters.
Buus NH; Aagaard TG; Mortensen AH; Jensen Jd; Møldrup U; Petersen SE
J Vasc Access; 2012; 13(2):226-30. PubMed ID: 22266590
[TBL] [Abstract][Full Text] [Related]
34. Nurse's guide to understanding and treating thrombotic occlusion of central venous access devices.
McKnight S
Medsurg Nurs; 2004 Dec; 13(6):377-82. PubMed ID: 15714740
[TBL] [Abstract][Full Text] [Related]
35. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial.
Pollo V; Dionízio D; Bucuvic EM; Castro JH; Ponce D
Hemodial Int; 2016 Jul; 20(3):378-84. PubMed ID: 26851872
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters.
Daeihagh P; Jordan J; Chen J; Rocco M
Am J Kidney Dis; 2000 Jul; 36(1):75-9. PubMed ID: 10873875
[TBL] [Abstract][Full Text] [Related]
37. Predicting tissue plasminogen activator use and success in in-center hemodialysis patients.
Kosa SD; Ye C; Thabane L; Gafni A; Lok CE
J Vasc Access; 2018 Mar; 19(2):146-152. PubMed ID: 28983900
[TBL] [Abstract][Full Text] [Related]
38. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
Hemmelgarn BR; Moist LM; Lok CE; Tonelli M; Manns BJ; Holden RM; LeBlanc M; Faris P; Barre P; Zhang J; Scott-Douglas N;
N Engl J Med; 2011 Jan; 364(4):303-12. PubMed ID: 21268722
[TBL] [Abstract][Full Text] [Related]
39. Use of tissue plasminogen activator in catheters used for extracorporeal renal replacement therapy.
Langston C; Eatroff A; Poeppel K
J Vet Intern Med; 2014; 28(2):270-6. PubMed ID: 24438008
[TBL] [Abstract][Full Text] [Related]
40. [Thrombosis and stenosis of central venous access in hemodialysis].
Vanherweghem JL
Nephrologie; 1994; 15(2):117-21. PubMed ID: 8047195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
